stockrowUFP Technologies, Inc.
UFPT Healthcare Medical Devices
UFP Technologies, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $602.8 million, up 19.5% from fiscal 2024.
- Revenue
- +11.6%
- EPS
- +25.6%
- Free cash flow
- −35.8%
- Total debt
- −40.2%
Quarter to September 2026, against a year earlier
Follow UFPT
Alert me
UFP Technologies, Inc. (UFPT) Net income
UFP Technologies, Inc.'s net income for fiscal 2025 was $68.3M, up 15.8% from $59.0M in fiscal 2024. Over the twelve months to 30 June 2026 it was $72.3M. Over the past ten years it has ranged from $7.6M (fiscal 2015) to $68.3M (fiscal 2025) — the current reading is the highest in ten years. Net income has risen for 5 consecutive fiscal years. UFP Technologies, Inc. ranks 25th of 149 Medical Devices companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $68.3M | 15.82% |
| FY2024 | $59.0M | 31.29% |
| FY2023 | $44.9M | 7.50% |
| FY2022 | $41.8M | 163.06% |
| FY2021 | $15.9M | 18.83% |
| FY2020 | $13.4M | (32.31%) |
| FY2019 | $19.8M | 38.01% |
| FY2018 | $14.3M | 55.39% |
| FY2017 | $9.2M | 15.56% |
| FY2016 | $8.0M | 4.97% |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Jun 2026 | $20.9M | 19.18% |
| Mar 2026 | $17.5M | (0.40%) |
| Dec 2025 | $17.6M | 7.22% |
| Sep 2025 | $16.4M | (4.64%) |
| 42 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| TMDX TransMedics Group, Inc. compare | $144.5M |
| INSP Inspire Medical Systems, Inc. compare | $100.7M |
| UFPT UFP Technologies, Inc. | $72.3M |
| AXGN AxoGen, Inc. compare | −$31.9M |
| ESTA Establishment Labs Holdings Inc. compare | −$38.9M |
| BFLY Butterfly Network, Inc. compare | −$53.7M |
| NEOG Neogen Corporation compare | −$56.1M |
| ALMR Alamar Biosciences, Inc. compare | −$77.7M |
| NVCR NovoCure Limited compare | −$121.7M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on UFPT
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement